alopecia

Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Market Analysis and Insights: Global Alopecia Treatment (Hair Loss) Market

The alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2020 to 2027 and is expected to reach USD 5,461.35 million by 2027. The rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) are the major drivers which propelled the demand of the alopecia treatment (hair loss) market in the forecast period.

Alopecia treatment comprises features such as increasing need for an effective treatment for alopecia (hair loss) which will impact in launching new products by the manufacturers into the alopecia treatment (hair loss) market which enhance its demand as well as rising pharmaceutical industries initiatives leads to the alopecia treatment (hair loss) market growth.

Currently, various research & clinical studies are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative alopecia treatment (hair loss) market. Moreover, these clinical programmes are also expected to provide various other opportunities in the alopecia treatment (hair loss) market. However, lack of awareness in rural countries and high cost of treatment is expected to restraint the alopecia treatment (hair loss) market growth in the forecast period.

The alopecia treatment (hair loss) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the alopecia treatment (hair loss) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the alopecia treatment (hair loss) market is segmented into non-cicatricial alopecia, cicatricial alopecia, traction alopecia and others. In 2020, the non‒cicatricial alopecia segment is dominating the alopecia treatment (hair loss) market as non‒cicatricial alopecia has the highest prevalence rate across the globe and affects a majority of the population.
  • On the basis of treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment. In 2020, localized therapies segment is dominating the alopecia treatment (hair loss) market due to first-line treatment to reduce the symptoms of alopecia and increase the hair growth.
  • On the basis of gender, the alopecia treatment (hair loss) market is segmented into male and female. In 2020, the male segment is dominating the alopecia treatment (hair loss) market due to the large number of male population affected by the androgenetic alopecia.
  • On the basis of form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral. In 2020, the topical segment is dominating the alopecia treatment (hair loss) market as a topical form offers patients with huge compliance and high satisfaction.
  • On the basis of end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres. In 2020, dermatology centres segment is dominating the alopecia treatment (hair loss) market because alopecia is a dermatology related disorder and required innovative treatment solutions for hair loss.
  • On the basis of the distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies. In 2020, pharmacies segment is dominating the alopecia treatment (hair loss) market because, for the treatment of alopecia or hair loss, majority of the formulation are available on OTC, which do not require a prescription and also offers patients with instant gratification.

Global Alopecia Treatment (Hair Loss) Market Country Level Analysis

Global alopecia treatment (hair loss) market is analyzed and market size information is provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of the Middle East and Africa.

Non‒cicatricial alopecia segment in North America region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 since it is the most common form of alopecia and people with alopecia aerate affects approximately 6.8 million people in the U.S. Japan is leading the growth of the Asia-Pacific alopecia treatment (hair loss) market and non‒cicatricial alopecia segment is dominating in the region due to rise in prevalence of alopecia and rising usage of hair care therapies for the treatment. The non‒cicatricial alopecia segment in Germany is dominating the European alopecia treatment (hair loss) market owing to the increasing demand for effective treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Continuous Increasing Awareness for Alopecia Treatment (Hair Loss) is boosting the Alopecia Treatment (Hair Loss) Market Growth

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in alopecia treatment (hair loss) industry with alopecia treatment (hair loss) drugs sales, the impact of advancement in the alopecia treatment (hair loss) technology and changes in regulatory scenarios with their support for the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2018.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to alopecia treatment (hair loss) market.

The major companies which are dealing in the global alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (a subsidiary of Endo International plc), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Aurobindo Pharma, Perrigo Company plc, Viviscal Limited (a subsidiary of Church & Dwight Co., Inc.), Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the alopecia treatment (hair loss) market.

For instance,

  • In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to enhance the sales of its product which is Rogaine, a hair loss treatment containing minoxidil. JW Pharmaceutical has signed an exclusive distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This initiative allowed the company to earn more product sales which has boosted the company’s overall revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the alopecia treatment (hair loss) market which also provides the benefit for the organization to improve their offering for alopecia treatment (hair loss).

Customization Available: Global Alopecia Treatment (Hair Loss) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Source

Recent Posts

Alopecia Treatment Market

Global Alopecia Drugs Market Report

Global Alopecia Drugs Market Report

The Alopecia Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Alopecia Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Alopecia Drugs market.

The report focuses on well-known providers in the global Alopecia Drugs industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Alopecia Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Key players in the global Alopecia Drugs market covered in Chapter 4

Dr. Reddy’s Laboratories Ltd
Cipla Inc.
Aqua Pharmaceuticals
Bayer HealthCare
Merck
Helix BioMedix
The Himalaya Drug Company
GlaxoSmithKline
Johnson & Johnson
AndroScience

In Chapter 11 and 13.3, on the basis of types, the Alopecia Drugs market from 2015 to 2026 is primarily split into:_x000D_

Oral
Topical
Injectable

In Chapter 12 and 13.4, on the basis of applications, the Alopecia Drugs market from 2015 to 2026 covers:

Men
Women

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Global Alopecia Drugs Market Report

Source

Recent Posts

Phase 2a trial evaluating CTP-543

Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA1 in 2022. A second Phase 3 trial, THRIVE-AA2, is expected to begin in the first half of 2021.

“Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer, Concert Pharmaceuticals. “We are fully committed to advancing CTP-543 with its Breakthrough Therapy designation in order to make a meaningful difference in the lives of individuals impacted by alopecia areata.”

The initiation of THRIVE-AA1 follows an end-of-phase 2 meeting where Concert discussed key aspects of its Phase 3 program and registration strategy with the U.S. Food and Drug Administration (FDA). The end-of-phase 2 meetings with the FDA was held following positive results from a dose-ranging Phase 2 trial of CTP-543 in patients with moderate to severe alopecia areata. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“There are millions of people around the world affected by and living with alopecia areata,” said Andy Bryant, Acting Chief Executive Officer of the National Alopecia Areata Foundation. “We’re encouraged by CTP-543’s potential to be one of the first FDA-approved medicines to treat alopecia areata.”

About the THRIVE-AA1 Study

THRIVE-AA1 (NCT04518995) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA1 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 700 patients;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 study, please visit https://clinicaltrials.gov/ct2/show/NCT04518995.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

Alopecia Treatment Market

Alopecia Market Size

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Up Market Research offers a latest published report on “Global Global Alopecia Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Alopecia Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Alopecia Market Research Report 2019 Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Alopecia Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Alopecia Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Alopecia Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Alopecia Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 6 Global Alopecia Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Alopecia Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Alopecia Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Alopecia Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Alopecia Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Alopecia Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Alopecia Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Alopecia Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Customization of the Report:

Up Market Research provides free customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

You can also ask for region wise market research report, as below:

• Global Alopecia Market Research Report 2019 Market – Global Market Status & Trend Report 2013- 2026 Top 20 Countries Data
• Global Alopecia Market Research Report 2019 Market – North America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – South America Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Europe Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – EMEA Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – Asia Pacific Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – China Market Status and Trend Report 2013- 2026
• Global Alopecia Market Research Report 2019 Market – India Market Status and Trend Report 2013- 2026

Alopecia Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region – Global Forecast To 2025

Recent Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020.

The oral presentation will highlight new data from an ongoing open-label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
  • Session: D1T03.3C: Late-Breaking News Session
  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology 2020

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Source

Previous Post

Thinning Hair and Hair Loss Product Market

Trial for Androgenic Alopecia in Men

Trial for Androgenic Alopecia in Men

The global hair transplant market size was USD 5.94 billion in 2018 and is projected to reach USD 43.13 billion by 2026, exhibiting a CAGR of 28.1% during the forecast period.

We are in process of revamping Hair Transplant Market with respect to COVID-19 Impact.

The hair transplant industry has rapidly undergone a pioneering transformation over the years. From the traditional Follicular Unit Transplantation (FUT) to Follicular Unit Extraction (FUE), the market has witnessed several technological advancements. Yet, it is still controversial for the physicians which transplantation method is the best so far.

Moreover, non-surgical procedures are also coming up with numerous advancements in medical devices for hair loss treatment. Pharmaceutical companies are focusing on R&D to launch an effective drug to assist hair loss.

As alopecia (commonly known as baldness) is very common among the populations in Asia Pacific and the Middle East & Africa, the hair restoration market is expected to exhibit an upsurging demand during the forecast period. In addition, growing investments in integrating robotics with transplantation technologies would also contribute to the faster growth of the market in the coming years.

Technological Advancements in Robotic Hair Transplantation to Propel Market Growth

Since the introduction of robotic hair transplantation, there have been continuous improvements in technology. Transplantation centres and top clinics are putting efforts into increasing the sophistication of the technique to yield effective treatment outputs. These efforts are facilitating market growth to a greater extent.

For example, recently in 2018, Restoration Robotics launched a 9x ARTAS robotic transplant system. The 9x ARTAS is the fastest and most accurate than the previous ARTAS version having better functionality. It has also been coupled with artificial intelligence (AI) to improve productivity and enhance system capabilities. Such technological advancements in the hair restoration industry would help grab a greater number of patients and yield better revenue during the forecast period.

Rapid Expansion of Patient Pool with Higher Disposable Income to Proliferate Market Potential

Due to the rapid advancements in the hair transplantation market, nearly all men and women who have alopecia can be successfully treated with these transplantation techniques. This achievement of the market has led to an increase in the patient population.

In the current scenario of the developing economies due to rising disposable income, men and women are largely spending on aesthetic procedures. This has led to the growth of the hair restoration market over the years.

According to the American Society of Aesthetic Plastic Surgery in 2016, Americans spent approximately USD 15 billion on surgical as well as non-surgical aesthetic procedures. Furthermore, based on the survey of Kaya Limited, there is a strong potential market in India owing to its rising disposable income and aspirational middle-class population.

Thus, considering the above points, it is anticipated that the hair restoration market has proliferative growth during the forecast period.

Increasing Prevalence of Androgenic Alopecia to Fuel Market Growth

Hair transplantation is the most common surgery performed in men worldwide. Androgenic alopecia is the term used for hair loss in men. According to the International Society of Hair Restoration Surgery (ISHRS), every year, approximately 35 million men in the U.S. are affected by male pattern baldness.

This increasing prevalence is likely to captivate patients towards hair restoration techniques and treatment options. Additionally, the launch of novel techniques and effective products are also expected to magnetize the patient population towards the hair transplant market during the forecast period. According to ISHRS, owing to the rising prevalence rates of alopecia, hair restoration procedures have been increased by 60% since 2014.

Out of the total surgeries performed, 87% of the patients are men. Therefore, increasing patient population and prevalence of androgenic alopecia are anticipated to elicit tremendous growth of the market during the forecast period.

High Surgical Procedure Cost to Limit the Growth of the Global Market

Even though transplantation technology has proved its effectiveness in restoring hair, the high cost of the procedure is likely to restrain the market growth. The transplantation procedure cost varies depending on the type of surgical technique preferred.

For instance, according to a study conducted by Robotics, average transplantation cost in the U.S. is around $16,000 and is highest among the other countries. Additionally, the average spending in developing countries such as India is around $3,000. Thus, the high procedure cost is unaffordable by the middle-income population of the countries and will limit the adoption of surgical procedures.

Higher Sales of Non-Surgical Hair Transplant Products to Lead Dominance

Based on type, the market is segmented into surgical and non-surgical. The non-surgical segment dominated the global market in terms of value and market share in 2018. The non-surgical restoration procedure is more advantageous as compared to that of the surgical procedure owing to its lesser side effects and instant results.

Due to such advantages, people are more attracted towards non-surgical hair transplantation. For instance, according to a survey conducted by the International Society of Hair Restoration Surgery (ISHRS), worldwide 1,241,764 patients for the non-surgical procedure were recorded in 2017. The sales of medications, devices to combat hair loss, and adoption of non-surgical techniques had led to the dominance of the segment in 2018.

On the flip side, though the surgical procedure segment had a lower market share in 2018, it is anticipated to gain traction during the forecast period. The segmental rise is attributable to the effectiveness of the surgical procedure. This segment is anticipated to have the highest CAGR and mark an exponential growth during the forecast period.

Adoption of Hair Transplants by Males to Aid Greater Market Share

Based on gender, the market is classified into male and female. The male segment dominated the global market in 2018. This dominance is attributed to the increasing number of surgeries undertaken by males all over the globe. The adoption of surgeries by the male segment of the population is higher owing to the occurrence of alopecia in 60% of the male than the female population.

A similar scenario is observed for the non-surgical procedures as well. For example, according to the data recorded by ISHRS in 2017, 85.7% of the male patients underwent surgical transplantation while 61.8% of the male patients underwent non-surgical procedures. The rising prevalence of alopecia in males is anticipated to mark the highest CAGR for the male segment during the forecast period.

Moreover, the female segment has recorded a lower hair transplant market share. Steady growth is anticipated during the forecast period owing to the lesser preference of females for transplantation of hair.

Growing Surgeries in Hospitals and Specialty Clinics to Aid Higher Market Value

By end-user, the global market is classified into hospitals & clinics and hair transplant centers. In 2018, the hospitals & clinics segment held the leading position in the market. The dominance is attributed to factors such as higher investments in infrastructure management and growing demand for surgical procedures by the patient population at hospitals and clinics. The hospitals and clinics have a well-established medical infrastructure and thus are of greater preference for the patient population.

The newly launched systems are adopted and installed by the hospitals and clinics in a short duration due to the availability of adequate funds. For instance, the popular ARTAS system by Restoration Robotics was sold in more than 37 countries globally to different hospitals and physicians.

On the other hand, these transplant centers segment is anticipated to showcase a slower growth during the forecast period owing to the generation of lower revenue by the centers. Also, a lack of awareness about the hair transplantation centers in the patient population would hinder the growth.

On the geographical front, the global market was dominated by Asia Pacific in 2018 in terms of market share and market value. The hair transplant market in Asia Pacific was valued at USD 1.88 billion in 2018. The primary factor responsible for the leading position is the highest number of transplantation surgeries of hair performed in the region. According to several research studies conducted by researchers, the populations in Asia Pacific have higher prevalence and chances of alopecia.

This has made the region a potential market for the investors. Additionally, the surgeries performed in the region have led to a generation of higher revenue leading to its dominance. Moreover, the establishment of hair transplant facilities in the region, coupled with higher investments in the advancements of the transplantation systems is contributing to the regional growth of Asia Pacific. Thus, the above factors are responsible to boost the region during the forecast period. The Middle East & Africa holds the second position in the market owing to the availability of the hair transplantation procedures at a lower value. This has led to the adoption of surgical procedures by the MEA population. However, the other factor contributing to the MEA market growth is the growing popularity of hair transplant surgery in Turkey.

On the other hand, North America and Europe are likely to exhibit a considerably lower market growth owing to a lower prevalence of alopecia in the countries and lesser adoption of these transplantation techniques.

Continuous Development of the Hair Transplant Systems Has Led Venus Concept a Leader

The global hair transplant market is fragmented into companies ranging from start-ups to well-established leaders. These market players are continuously focused on developing innovative products to achieve effective transplant procedures and positive outcomes.

Venus Concept has surpassed the other players through rigorous developments and launching of surgical as well as non-surgical treatment products. ARTAS iX robotic system has become one of the most demanding systems worldwide. This system helps to assist physicians in identifying and extracting hair follicular units from the scalp of the alopecia patients. Venus Concept after merging with Restoration Robotics Inc. brought this ARTAS system and has leveraged its potential in the hair restoration market.

Trial for Androgenic Alopecia in Men

Source

Previous Post

Alopecia Treatment Market

Global Alopecia Market

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Eon Market Research has added a report titled “Global Alopecia (Hair Loss Treatment) Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025”. The report will include the impact of COVID 19 and its impact on the growth of this industry during the forecast period.

The Alopecia (Hair Loss Treatment) market report offers the growth scenarios present globally as well as revenues of the overall market. The Global Alopecia (Hair Loss Treatment) market report thoroughly discusses robust growth prospects and prominent strategies implicated by several key players operating in the global market, which are likely to benefit the market growth and grab a leading position in terms of revenue in the Alopecia (Hair Loss Treatment) market.

In this report, the global Alopecia (Hair Loss Treatment) market is estimated at USD XX million in 2020 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2020 and 2025.

Geographically, this report is segmented into various key Regions

North America
Europe
China
Japan
Southeast Asia
India

Global Alopecia (Hair Loss Treatment) market competition

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter and Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Based on product

Shampoos and Conditioners
Medicine Product

Based on the end users/applications

Men
Women

Global Alopecia Market Research Report 2020 Analysis, Demand, Insight, Key Players, Segmentation and Forecast to 2025

Source

Previous Post

Alopecia Treatment Market

Global Alopecia Market Insights

Global Alopecia Market Insights and Forecast to 2026

Alopecia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alopecia market will be able to gain the upper hand as they use the report as a powerful resource.

The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Alopecia market is segmented into

Oral treatment
Topical treatment
Other treatment

Segment by Application, the Alopecia market is segmented into

Male
Female

Regional and Country-level Analysis

The Alopecia market is analysed and market size information is provided by regions (countries).

The key regions covered in the Alopecia market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes a country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Alopecia Market Share Analysis

Alopecia market competitive landscape provides details and data information by players. The report offers a comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020.

It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Alopecia business, the date to enter into the Alopecia market, Alopecia product introduction, recent developments, etc.

The major vendors covered:

Lifes2good
Kirkland Signature
Johnson & Johnson
Dr Reddys Laboratories.
Cipla.
Alpecin.
Vitabiotics.
Sun Pharma.
Phyto Ales Group

Global Alopecia Market Insights and Forecast to 2026

Source

Previous Posts

Alopecia Treatment Market

Androgenic Alopecia Global Clinical Trials

Androgenic Alopecia Global Clinical Trials Review, H1, 2020

Summary

The clinical trial report, “Androgenic Alopecia Global Clinical Trials Review, H1, 2020″ provides an overview of Androgenic Alopecia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Androgenic Alopecia.

The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials). Clinical Trial Reports are generated using proprietary database – Pharma – Clinical trials database.

Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision-making capabilities and helps to create an effective counter-strategy to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– The report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with a reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– The report provides the latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Androgenic Alopecia Global Clinical Trials Review, H1, 2020

Source

Previous Posts